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Background: Components of the extracellular matrix have been studied in an attempt to elucidate the
mechanisms involved in the biological behaviour of tumours. The presence of the proteoglycan versican has been
strongly associated with cancer development and progression. However, relationship between versican expression
and clinical pathological factors and overall survival has not been previously studied in veterinary medicine.
Carcinomas in benign mixed tumours (CBMTs) are one of the most common malignant tumours in female canines
and can serve as models for studies of tumour progression. The aim of this study was to evaluate the expression of
versican in in situ and invasive carcinomatous areas of canine CBMTs and to evaluate possible associations of
versican expression with other classic prognostic factors and overall survival.
Results: Clinical staging; histological grade determination; immunohistochemical staining for versican, E-cadherin
and Ki-67; and confirmation of invasion areas by staining for p63 and smooth muscle α-actin (α-SMA) were
performed on 49 canine cases of CBMT. Tumour invasion was considered when suspicious Haematoxylin-Eosin
(HE)-stained areas showed a total loss of α-SMA and p63 immunoreactivity. Versican immunoreactivity was less
intense in the areas adjacent to the in situ carcinomatous regions, compared to invasive regions, which showed
extensive and strong staining.
Conclusions: Our data reveal that in canine CBMTs, versican expression differs significantly between invasive and
in situ areas, suggesting a role for this molecule in tumour progression. Although a direct relationship exists
between versican and invasiveness, our results indicate that the isolated evaluation of this proteoglycan does not
represent an independent prognostic factor in canine CBMTs.
Keywords: Versican, Mixed tumour, Carcinoma, Invasion, CanineBackground
Mammary neoplasms are the most common proliferative
lesions among female dogs [1], representing approxi-
mately 52% of all neoplasms. The malignant ratio of
these tumours is variable, with an average of 50% [2-4].
Canines between seven and eleven years of age are the
most commonly affected [5-7].* Correspondence: cassalig@icb.ufmg.br
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distribution, and reproduction in any mediumAmong malignant canine mammary tumours, carci-
nomas in benign mixed tumours (CBMTs) are the
most common histological type in the authors’ expe-
riences [3,8]. These tumours originate from a malig-
nant transformation of the epithelial component of a
benign mixed tumour. This carcinomatous proliferation
may occur as in situ or infiltrative growth, as demon-
strated either by a loss in continuity of the myoepithe-
lial and basal layers associated with the neoplastic cells
invading the stroma or by complete replacement ofntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
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pathological examination [9].
Since the 1970s, authors have defended the malignant
progression hypothesis in benign canine mammary mixed
tumours [10]. More recently, protein alterations that may
contribute to the transformation of benign mixed tumours
have been observed, such as the loss of p63, ΔNp63,
E-cadherin, β-catenin and EGFR overexpression [11-13].
Genetic factors that result in the malignization process
are still relatively unknown. However, phenotypic evalua-
tions of myoepithelial cells and extracellular matrix com-
ponents have been performed in the attempt to clarify
the mechanisms involved in the biological behaviour of
these tumours [14].
Among the extracellular matrix components, the pro-
teoglycan versican has caught the attention of research-
ers [15,16]. Versican is produced by stromal cells in a
wide range of mature tissues, including smooth muscles,
cartilage, and skin [17]. Some studies also suggest that
versican is involved in cancer development and progres-
sion [15,18,19] because higher expression levels have
been associated with local invasion and angiogenesis in
breast cancer in women [16].
Elevated versican expression in peritumoural stromal
tissues has also been associated with histological gradeFigure 1 Carcinoma in benign mixed tumour. A. In situ carcinomatous a
with Mayer’s haematoxylin counterstain, 40×. B. In situ carcinomatous area
stain with Mayer’s haematoxylin counterstain, 40×. C. Versican moderate ex
Mayer’s haematoxylin counterstain, 40×. D. Versican overexpression adjacen
haematoxylin counterstain, 40×.and may be a strong factor in predicting disease relapse
in lymph node negative breast cancer patients [20]. The
mechanisms that alter the expression of this proteogly-
can are still poorly understood; however, its role in
modulating the loss of adhesion and cell motility has
also been recognised in cases of breast cancer metastasis
[16,20].
Researchers have demonstrated that in canine mam-
mary tumours, versican is highly expressed in prolifera-
ting fusiform cells and in myxoid areas of the mixed
tumours [21]. Versican accumulation in myoepithelial
tumours is related to the early differentiation of the
myxoid matrix to cartilage. In prior studies, these same
authors observed increased versican expression in areas
of tumour infiltration [14].
Considering that CBMTs can serve as research
models for tumour progression [13,22], the analysis of
versican expression in these tumours can contribute
to the understanding of the transformation and pro-
gression mechanisms in malignant mammary tumours.
In this context, the present work aims to evaluate the
expression of the proteoglycan versican in in situ and
invasive carcinomatous areas in canine CBMTs and to
verify its association with other prognostic factors and
overall survival.rea with low stromal versican expression. Immunohistochemical stain
with moderate stromal versican expression. Immunohistochemical
pression adjacent to invasive area. Immunohistochemical stain with
t to invasive area. Immunohistochemical stain with Mayer’s
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Versican expression in peritumoural stroma
Proteoglycan versican immunoreactivity in areas adjacent
to the in situ carcinomatous regions were less intense
(median, 140.0) compared to the areas adjacent to the
invasive regions (median, 280.0), which were characterized
by more extensive areas of strong versican expression
(Figures 1 and 2).
Table 1 presents the results of the versican analysis
and shows the intensity and percentage of the stained
areas in both the in situ and invasive regions.
Clinical and pathological features
The present study demonstrated a higher incidence of
the disease among Poodles (55.77%), followed by mongrel
dogs (9.62%) and Doberman Pinschers (9.62%). The age of
the dogs varied from 4.5 to 19 years, with a mean age of
10.5 years. Comparative analyses of the clinical and patho-
logical characteristics among these groups are presented
in Table 2.
Invasion, loss of adhesion, and proliferation index
The evaluation of the myoepithelial cell layer integrity
was performed through analysis of p63 and α-SMA
immunoreactivity (Figure 3). The in situ areas were
defined through the observation of epithelial cells thatFigure 2 Immunoreactivity for p63, α-SMA, E-cadherin and Ki-67 in in
areas for p63 and α-SMA (a) and e-cadherin (b) demonstrated by immunoh
areas when compared to in situ areas (c). *Spearman correlation. §Wilcoxonwere in a tubular arrangement with basal membrane in-
tegrity shown by HE staining and cells that were double-
positive for p63 and α-SMA.
Invasion was considered when suspicious HE-stained
areas revealed a total loss of immunoreactivity for α-
SMA and p63, thus denoting a loss of myoepithelial cells
in gaps corresponding to a three-cell space [23]. These
results are represented in Table 3.
Rupture of the basal membrane, which is associated
with the observation of malignant epithelial cells in the
adjacent stroma, was also observed by PAS staining
(Figure 3).
Evaluation of p63 and α-SMA staining in carcinomas
with invasion areas showed that there was a loss of, or
weak staining for, at least one marker in the remaining
myoepithelial cells, which differs from observations in
in situ areas, in which double-positive staining was no-
table. A significant difference was observed in p63 and
α-SMA expression between in situ and invasive areas,
with P < 0.0001 (Figure 2).
E-cadherin, an adhesion molecule, expression in in situ
and invasive areas (Figure 4) was evaluated to investigate
its possible relationship with versican. In situ carcinoma-
tous areas revealed strong and diffuse immunoreactivity
for E-cadherin, whereas invasive areas showed weak or ab-
sent staining. In tumours with low (group 1) and highsitu and invasive areas. Difference between in situ and invasive
istochemistry. Accumulation of versican in invasive carcinomatous
test.
Table 1 Versican immunohistochemistry evaluation in mammary carcinomas in benign mixed tumours in female dogs
Areas Parameters All Score Group 1 (n = 25) Group 2 (n = 24) P value




Percentage of the tissue section
stained positive (mean)
49 43.24 68.96




Percentage of the tissue section
stained positive (mean)
49 67.6 88.96
P value <0.0001 <0.0001
Group 1, represented by cases with low versican expression; and Group 2, represented by cases with versican overexpression.
Wilcoxon Test.
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the expression of E-cadherin was observed between the in
situ and invasive areas, with P < 0.0001 (Figure 2). How-
ever, no statistically significant correlation could be
observed between versican and E-cadherin expression.Table 2 Association between pathological and clinical









Lymph node metastasis 6/49 3/25 3/24 -
Pulmonary metastasis 1/49 0/25 1/24 -
Size
< 3 cm 28/49 13/25 15/24
3 < x < 5 11/49 6/25 5/24 0.3735
≥ 5 cm 10/49 6/25 4/24
Clinical staging
I 24/49 12/25 12/24
II 11/49 6/25 5/24
III 7/49 4/25 3/24 0.9657
IV 6/49 3/25 3/24
V 1/49 0/25 1/24
Histological grade 0.714
I 44/49 21/25 23/24
II 5/49 4/25 1/24
III 0/49 0/25 0/24
Group 1, represented by cases with low versican expression; and Group 2,
represented by cases with versican overexpression.
Student’s t- test was used for parametric data (size).
Fisher’s exact test used for categorical variables (clinical staging and histological
grade).Survival curves
Considering only versican expression, overall survival
was found to be longer in female dogs with low immu-
nostaining for this proteoglycan than in dogs with high
immunostaining; however, no statistically significant dif-
ference was observed (P = 0.1947) (Figure 5).
Overall survival was analysed in 40 cases. Thirty-two
(80%) dogs remained alive at the end of the study, four
(10%) dogs died during the study and four (10%) were
censored due to loss of follow-up or death unrelated to
the tumour.
Discussion
The proteoglycan versican is one of the most studied
components of the extracellular matrix associated with
human breast cancer [24]. Versican is synthesized mainly
by stromal cells and possesses anti-adhesive properties
that interfere with cell motility [25]. This property
appears to be related to the association of versican with
hyaluronic acid, which exhibits altered expression in neo-
plastic conditions [26].
The most important criteria for the diagnosis of inva-
sion in mammary carcinomas is the absence of myoe-
pithelial cells surrounding neoplastic proliferations
associated with basal layer rupture [23]. Nevertheless,
the recognition of these areas based solely on HE stain-
ing evaluation can be quite difficult. Therefore, staining
for p63, α-SMA and PAS was implemented to aid in the
evaluation of invasive regions.
In this study, myoepithelial cells revealed a progres-
sive loss of immunoreactivity for both p63 and α-SMA
from in situ to invasive areas. In in situ areas, the ab-
errant expression of these molecules suggests that
myoepithelial cells have suffered dedifferentiation and no
Figure 3 Carcinoma in benign mixed tumour. A. In situ carcinomatous area in a carcinoma in benign mixed tumour. HE, 60×. B. Evidence of
an intact basement membrane. PAS, 60×. C. Integrity of the myoepithelium layer demonstrated by p63 and α-SMA double staining. 60×.
D. Microinvasion area in carcinoma in benign mixed tumour (arrow). HE, 60×. E. Discontinuous basement membrane (arrow). PAS, 60×.
F. Absence of p63 and α-SMA expression (arrow), 60×.
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molecules [12,27,28]. In sites suspected of invasion, the
absence of p63 and α-SMA staining denotes a flaw in the
myoepithelial layer, which in association with the discon-
tinuity of the basal membrane, confirms the lesion. In
such sites, double-staining immunohistochemistry is
useful for evaluating these areas.
Once areas with infiltration of neoplastic cells in the ad-
jacent stroma were confirmed, the presence of versican
was evaluated. Versican expression differed significantly
between in situ and invasive areas (P < 0.0001), both in
cases of low and of high versican expression. There was
also statistically significant difference (P = 0.0002) in the
versican immunoreactivity in the in situ areas between the
two groups (1 and 2). In addition, a significant difference
was observed when comparing versican immunoreactivity
in invasive and in situ areas (P < 0.0001), suggesting a di-
rect relationship between versican and invasion.
Researchers have previously analysed versican expression
in areas adjacent to in situ and invasive carcinomatousareas in human breast cancer [24]. The mechanisms
involved in cell and stromal interaction are believed to lead
to the development of invasive lesions from in situ mam-
mary lesions. Furthermore, elements typically expressed in
the invasive stroma, such as versican, suggest that pre-
invasive lesions can acquire some characteristics com-
monly attributed to invasive areas, most likely contributing
to the progression of neoplastic processes.
Many authors have also shown that extracellular matrix
components, including the proteoglycan versican, play a
critical role in facilitating the progression and dissemi-
nation of malignant neoplastic cells [14,18,19,26,29-31].
Mukaratirwa and colleagues (2004) observed a significant
correlation between stromal immunoreactivity intensity
for versican and invasion in colorectal carcinomas in dogs,
suggesting that this proteoglycan supports tumour pro-
gression [26]. The carcinomatous cells that invade the
stroma are believed to be capable of stimulating fibro-
blasts to produce versican, which in turn plays a crucial
role in tumour progression.
Table 3 Evaluation for PAS and association with




Group 1 Group 2 Group 1 Group 2
p63 0 0/20 1/21 12/21 13/21
1 0/20 3/21 6/21 5/21
2 7/20 6/21 3/21 3/21
3 13/20 11/21 0/21 0/21
α-SMA 0 1/20 6/21 13/21 14/21
1 5/20 5/21 8/21 6/21
2 4/20 3/21 0/21 1/21
3 10/20 7/21 0/21 0/21
E-cadherin 0 0/24 0/24 17/25 15/24
1 3/24 7/24 8/25 9/24
2 21/24 17/24 0/25 0/24
Ki-67 (Mean value) 5.6 (22) 8.7 (22) 5.62 (22) 12 (22)
Group 1, represented by cases with low versican expression; and Group 2,
represented by cases with versican overexpression.
Significant differences at P < 0.0001 between in situ and invasive areas in p63,
α-SMA, and e-cadherin using the Wilcoxon Test.
Figure 5 Survival rates of animals with canine mammary
carcinomas in benign mixed tumours. Survival curves were
estimated with the Kaplan-Meier method followed by the log-rank
test. Group 1, represented by cases with low versican expression;
and Group 2, represented by cases with versican overexpression.
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expression and clinico-pathological factors was evaluated
to verify the biological significance and prognostic value
of versican. However, no statistically significant relation-
ship was observed between the evaluated prognostic fac-
tors and high or low expression of versican or between
the prognostic factors and versican staining in in situ
and invasive areas. These results may be explained by
the fact that the studied cases mostly represented low
grade, nonaggressive tumours associated with a good
prognosis, suggesting that our samples were somewhat
homogenous. Furthermore, no association was found be-
tween the evaluated biological factors and the immuno-
histochemical expression of versican in human
pharyngeal squamous cell carcinomas [15]. In non-small
cell lung cancer, versican has been shown to beFigure 4 Carcinoma in benign mixed tumour. A. In situ carcinomatous ar
stain with Mayer’s haematoxylin counterstain, 40×. B. Loss of E-cadherin expressio
haematoxylin counterstain, 40×.associated with an unfavourable prognosis but is not
considered to be an independent indicator of patient
survival [32]. Finally, in ovarian cancer, versican expres-
sion does not appear to have prognostic significance,
despite the finding that high stromal staining is related
to poor disease-free survival [33].
Versican has also been linked to neoplastic cell adhe-
sion and proliferation [15,16,21,34-37]. A potential
significant role for the G3 versican domain, with its
EGF-like motif, in influencing tumour cell viability, pro-
liferation and local tumour growth has been suggested
[16]. Some studies also suggest that versican expression
is involved in an increase in cell proliferation, apoptosis-
resistance and the regulation of the cadherin family
protein expression, inducing mesenchymal-epithelial
transitions [38,39]. Versican isoforms v1 and v2 seem to
play distinct roles in cell proliferation functions that are
mediated by the GAG-α and GAG-β domains, respect-
ively [34,38]. It has been shown that the GAGβ domain
is responsible for activation, whereas the GAGα domain
plays a role in the suppression of epidermal growth factor
receptor (EGFR) expression and its downstream signaling
pathway [38]. The extracellular environment might be-
come favourable for cell proliferation and survival whenea with high E-cadherin expression in cell membrane. Immunohistochemical
n in invasive carcinomatous cells. Immunohistochemical stain with Mayer’s
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lopment and tumour formation [38].
In canine mammary tumours, the mechanisms that regu-
late the signal pathways and the role of the different iso-
forms remain poorly elucidated. In this study, no difference
regarding the proliferation index was observed between
low and high versican expression groups. Thus, Ki-67 ex-
pression did not indicate a relationship between proteogly-
can overexpression and tumour proliferation in CBMTs.
Studies indicating a relationship between versican and
E-cadherin expression in epithelial tumours are scarce.
Therefore, one goal of this study was to investigate the
association between versican and E-cadherin. However,
despite the existence of statistically significant differ-
ences between both E-cadherin and versican expression
in in situ and invasive areas, no relationship between the
two molecules was observed in CBMTs. This finding
most likely indicates that versican expression interferes
in carcinomatous cell adhesion through other mechanisms
that are not yet understood.
Conclusions
Our data reveal that in CBMTs, versican expression differs
significantly between invasive and in situ areas, suggesting
a role for this molecule in tumour progression. However,
no associations between the proteoglycan and prognostic
factors could be observed. Therefore, although a direct
relationship exists between versican expression and
invasiveness, our results indicate that isolated evaluation
of this proteoglycan does not represent an independent
prognostic factor for canine CBMTs.
Methods
Case selection
To carry out this study, 49 cases of CBMTs were selected
at the Comparative Pathology (Universidade Federal de
Minas Gerais) and Pathological Anatomy Laboratories
(Universidade Federal da Bahia). Samples of mammary
tumours were obtained from female dogs, regardless of
breed or age, that had undergone mastectomy. Clinico-
pathological parameters, including tumour size, lymph
node metastasis, pulmonary metastasis, clinical stage and
histological grade were used in comparative analyses
between low and high versican expression groups.
According to the a median expression of versican in
invasive areas, two distinct categories were determined:
Group 1, represented by cases with values of versican
expression that were lower than the median; and
Group 2, represented by cases with values of versican
expression that were higher than the median.
Clinical staging: TNM
Clinical staging was based on tumour size (T), regional
lymph node involvement (N) and presence of distantmetastasis (M) and was determined according to the
TNM staging system, established by the World Health
Organization (WHO) for canine mammary tumours
[40]. Data were obtained from a retrospective review of
the clinical, radiological, and pathological records of all
animals.
Histological classification and grading
Fragments of the affected mammary glands that included
skin and subcutaneous tissues were fixed in phosphate-
buffered 10% neutral formalin and processed by the routine
technique of paraffin embedding. Histological sections of
4 μm were obtained from the tumour samples and stained
using HE [41]. In all cases, duplicate slides were prepared
and analysed by two veterinary pathologists, and the con-
firmation of the histological type followed the standards pro-
posed by Misdorp et al. (1999) [42].
Histological analyses of 49 lymph nodes were further
performed to categorise tumour samples with or without
lymph node metastasis.
The tumours were graded by the Nottingham System
[43], and the criteria included tubular formation, nuclear
pleomorphism and mitotic index. Mitotic activity was deter-
mined as the number of mitotic cells per 10 fields, per-
formed by two independent analysts in a blinded fashion,
using an Olympus BX-40 microscope fitted to a 10× eye
piece and a 40× objective. Using this equipment, one high-
power field visualises an area of 0.239 mm2 [44].
Immunohistochemistry
The following monoclonal antibodies were used in the
present study: versican (12C5, DSHB, 1:50), p63 (4A 4,
Neomarkers, 1:80), smooth muscle α-actin (α-SMA) (1A
4, Dako, 1:100), E-cadherin (NCH-38, Dako, 1:60) and
ki-67 (Mib-1, Dako, 1:25). Three micrometre tissue sec-
tions were cut from one representative block of each
case and collected onto glass slides. Tissue sections were
deparaffinised in xylene, subjected to heat-induced anti-
gen retrieval with an antigen retrieval solution (DAKO)
at pH 6.0 in a water bath at 98°C for 20 min, and then
incubated for 60 minutes at room temperature with the
monoclonal antibodies (all except versican). For versican
antigen retrieval, chondroitinase ABC (from Proteus vul-
garis; Sigma Chemicals) digestion was performed at 37°C
for 90 min with 0.5 U/mL of the enzyme in 0.25 M Tris
buffer (pH 8.0) containing 0.18 M sodium chloride and
0.05% bovine serum albumin (BSA). Next, 0.25 M Tris
buffer (pH 8.0) containing 0.1 M 6-amino-n-caproic-acid
and 5 mM benzamidine hydrochloride was used to in-
hibit protease activity for 30 min [21]. Slides were incu-
bated overnight at 4°C with the monoclonal antibody
12C5. An endogenous peroxidase activity block was per-
formed with 3% hydrogen peroxidase in methanol. A
biotin-peroxidase system was then used in the
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the secondary antibody using a polymer (ADVANCE
HRP–ready to use–DakoCytomation). Diaminobenzidine
was used as a chromogen, and the sections were coun-
terstained with Mayer’s haematoxylin, dehydrated, and
mounted in synthetic medium. The EnVisionTM G|2 Dou-
blestain System Kit, Rabbit/Mouse (DAB+/Permanent
Red) was used for the double-staining immunohisto-
chemical technique (used to identify p63/ α-SMA).
Negative controls were obtained by omitting the primary
antibodies. Adjacent normal canine mammary tissues were
used as positive controls for p63, α-SMA and E-cadherin.
Canine mammary tumours previously known to express
high levels of Ki-67 and abundant myxoid tissues were used
as positive controls for Ki-67 and versican, respectively.
Immunohistochemical evaluation
Areas previously suspected of stromal invasion by HE
staining were confirmed through the presence of both
p63 and α-SMA. Immunoreactivity for p63 and α-SMA
was assessed semiquantitatively using a scoring system:
(−) no staining, (+) weak or <5% of stained myoepithelial
cells, (++) moderate or between 5 and 50% stained
myoepithelial cells, and (+++) strong or 50% of stained
myoepithelial cells [12].
In situ and invasive carcinomatous areas of CBMTs
were analysed in at least five fields in this study. In these
areas, versican expression was assessed by semiquantita-
tive scoring [31] that includes (i) the overall percentage
of the tissue section stained positive (0-100%), and (ii)
the signal intensity (4-point scale) for each proteoglycan.
The scoring used for the 4-point scale was as follows: 1,
negative or very weak staining; 2, weak positive; 3, mode-
rate positive; and 4, strong positive. The semiquantitative
immunohistochemical (IHC) score for the expression
level of each proteoglycan was provided by the multipli-
cation of the percentage (0–100) of the tissue section
staining positive by the factor (1–4) corresponding to the
staining intensity of the tissue section. According to the
final results of this evaluation, a median versican expres-
sion score (280.0) was obtained for invasive areas. Thus,
two distinct categories were determined: Group 1, repre-
sented by cases with values of versican expression con-
sidered lower than the median, and Group 2, represented
by cases with values of versican expression that were
higher than the median.
Ki-67 staining was considered positive when cell nuclei
presented a diffuse nuclear staining pattern. Ki-67 proli-
ferative activity was assessed with an image analysis de-
termining the percentage of positive cells among 1000
tumour cells (proliferation index) [44].
E-cadherin staining of the membranes of neoplastic
epithelial cells was evaluated in in situ and invasive
areas. Immunostaining intensity for E-cadherin wasevaluated qualitatively and scored as follows: 0 = nega-
tive, when the staining was absent; 1 =moderate, when
the staining was weaker than in normal epithelium; and
2 = strong, when the staining was equal to that observed
in normal mammary epithelium [45].
Histochemistry
Periodic Acid Schiff (PAS) staining was performed on all
sections. This reaction indicates the presence of polysac-
charides in the basal membrane and verifies the integrity
of this structure [46].
Statistical analysis
To determine whether continuous variables (size, age,
Ki-67) differed between groups with low and high versi-
can expression, Student’s t-test was used for parametric
data, and the Mann–Whitney Test was used for non-
parametric data. For categorical variables, such as lymph
node metastasis, clinical staging, mitotic index, histo-
logical grade, and α-SMA and p63 expression, Fisher’s
exact test was performed.
Differences in versican, Ki-67, p63, α-SMA and E-
cadherin expression between in situ and invasive areas
were evaluated by the Wilcoxon Test.
Kaplan Meyer analysis (log-rank test) was used to
evaluate overall survival. Values were considered statisti-
cally significant when P < 0.05. Overall survival was
defined (in days) as the period between surgical excision
of the primary tumour and the death of the animal due
to the disease. Animals with loss of follow-up or death
unrelated to the tumour were censored.
Clinical follow-up of the 40 animals included in the
overall survival analysis was performed from 2008 to
2011 through periodic telephone communication and re-
turn visits to the Veterinary Teaching Hospital of the
Federal University of Minas Gerais. Overall survival time
was defined as the period (in days) between the date of
surgical removal of the tumour and death caused by the
disease. Animals that died from unknown causes or
causes unrelated to the tumour were censored.
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